Curis, Inc. · NASDAQ:CRIS
Curis — Investor Presentation (September 2006)
41 slides from Curis's investor presentation, Sep 13, 2006
Slide 1: Curis, Inc. Corporate Presentation
Curis, Inc. (NASDAQ: CRIS) Corporate Presentation September 12, 2006 Confidential September 12, 2006 1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains statements about Curis’ future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially f
Slide 3: Curis Business Strategy
Curis Business Strategy A Balanced Business Model A Portfolio Approach to Drug Development Partnerships with top-tier Pharma expected to provide validation, access to world leading drug development competencies, higher probabilities of success and reduce reliance upon capital markets Potential cash
Slide 4: Genentech, Wyeth
a Genentech Wyeth Genentech
Slide 5: Curis Model: Anticipated Near Term Milestones
Curis Model: Anticipated Near Term Milestones Disco Target Med Preclinical IND Clinical Phases Products HTS very Valid Chem Early Mid Late Multi-Target Hh IND Filing Oncology Drug Pipeline Oncology A-B4 Anticipated 2H’06 A – B1 A – B2 A-B5 Selection of Lead A – B3 Hh Anticipated 1H’07 Neurology Undi
Slide 6: Curis Model: Proprietary Drug Platform
Curis Model: Proprietary Drug Platform Disco Target Med Preclinical IND Clinical Phases HTS very Valid Chem Early Mid Late Products I II III Multi-Target Oncology Drug Pipeline A-B4 A – B1 A – B2 A-B5 A – B3 Single agent targeting 2 or more validated targets (A+B): - Novel, Proprietary Compounds - V
Slide 7: Curis Model: Proprietary Drug Platform
Curis Model: Proprietary Drug Platform Disco very Target Valid Clinical Phases Products I II III Multi-Target Oncology Drug Pipeline Curis is seeking to use this novel approach to provide combination therapeutic synergies with reduced toxicity profiles of well validated targets / drugs as single age
Slide 8: Rationale for Validated Targets and Validated Drug Prototypes
Rationale for Validated Targets and Validated Drug Prototypes Starting with validated disease targets and known prototype drugs expected to 1. Reduce risks 2. Reduce costs 3. Greatly speed development time Source: CCL Research of Published Data
Slide 9: Rationale for Multi-Target Inhibitors
Rationale for Multi-Target Inhibitors The heterogeneity of cells within tumors as well as the redundancy of proliferative and survival pathways favor the development of drugs that affect multiple pathways Multi-targeted compounds that act synergistically are expected to lead to superior efficacy wit
Slide 10: Anti-Proliferative Activity of Multi-Target Inhibitors
Anti-Proliferative Activity of Multi-Target Inhibitors in A431 Epithelial Carcinoma Cells (%) 80 Inhibition Proliferative A B CUR MTI-1 CUR MTI-2
Slide 11: Apoptotic Effects of Multi-Target Inhibitors
Apoptotic Effects of Multi-Target Inhibitors on EGFR Inhibitor-Insensitive Cancer cells Caspase 3/7 (fold change) 3.0 B Target Inhibitor EGFR Inhibitor 2.5 CUR MTI-1 CUR MTI-2 2.0 1.5 1.0 0.5 0.001 0.01 0.1 1 10 100 Concentrations (u M)
Slide 12: Synergy and Multi-Target Inhibitor Design
Target A Inhibitor Synergy and Multi-Target Inhibitor Design B = CDK MEK Inhibitor Inhibitor Multikinase Inhibitor 1 EGFR Inhibitor Multikinase Inhibitor 2 VEGFR Drug A B Inhibitor Retinoic acid Bcr-Abl Inhibitor DNMT Proteasome Inhibitor Others Inhibitor
Slide 13: Proprietary Drug Platform
Proprietary Drug Platform Multi-Targeting Drug Platform: A - B A1- B1, B2 , B3… A2- B1, B2 , B3… A3- B1, B2 , B3… A4- B1, B2 , B3… Dramatic need for enhanced med chem capacity to fully exploit the promise platform approach • US/EU cost prohibitive = China solution • More effective/efficient process
Slide 14: Curis Shanghai
Curis Shanghai Curis has created a Chinese subsidiary Operations to be located in Zhangjiang Hi-tech Park, Pudong, Shanghai Subsidiary to utilize CRO medicinal chemistry Cost of chemistry expected to approximate 25% of U.S. chemistry providers Expected to allow for a greater number of drug programs
Slide 15: Rationale for China
Rationale for China The formation of a Chinese subsidiary is expected to allow Curis to capitalize on the mature medicinal chemistry industry that exists in China Cost savings expected to allow Curis to increase number of drug programs and retain drug programs beyond the mid-preclinical phase Wholly
Slide 16: Curis Model: Core Competencies and Enhanced Capacity
Curis Model: Core Competencies and Enhanced Capacity & Productivity (Curis China) Disco Target Med Preclinical IND Clinical Phases Products HTS very Valid Chem Early Mid Late I II III Back-up #2 Lead Drug Lead Back-up #1 Curis Curis Curis US China US
Slide 17: Curis Model: Core Competencies and Enhanced Capacity
Curis Model: Core Competencies and Enhanced Capacity & Productivity (Curis China) Disco Target Med Preclinical IND Clinical Phases Products HTS very Valid Chem Early Mid Late I II III Back-up #2 Lead Drug Lead Back-up #1 Curis Curis Curis US China US
Slide 18: Curis Model: Core Competencies and Enhanced Capacity
Curis Model: Core Competencies and Enhanced Capacity & Productivity (Curis China) Disco Target Med Preclinical IND Clinical Phases Products HTS very Valid Chem Early Mid Late I II III Back-up #2 • Enhanced Capacity Lead • Decreased Cost Drug Lead • Increased Productivity Back-up #1 • Decreased Time:
Slide 19: Curis China – ChemPartner CRO
Curis China – ChemPartner CRO Confidential
Slide 20: Partner-Program Status Update
Partner-Program Status Update Disco very Target Valid HTS Products Undisclosed Pathway Screens Med Preclinical IND Clinical Phases HTS Chem Early Mid Late I II III Hh Oncology Hh Neurology Undisclosed Pathway Screens Hair Re-Growth Hh Agonist Screens BMP-7 BMP-7 Small Molecule Cardio Screens
Slide 21: Partner-Program Status Update
Partner-Program Status Update Disco very Target Valid HTS Products Target Med Preclinical IND Clinical Phases HTS Valid Chem Early Mid Late I II III Hh Oncology Hh Neurology Undisclosed Pathway Screens Hair Re-Growth Hh Agonist Screens BMP-7 BMP-7 Small Molecule Cardio Screens Hh Agonist Screens BMP
Slide 22: Hedgehog-Associated Cancers
Hedgehog-Associated Cancers Medulloblastoma1 Small Cell Lung Cancer 2 Pancreatic Carcinoma 3,4 Stomach Cancer 4 Esophageal Cancer 4 Colorectal Cancer 5 Prostate Cancer 6,7,8 Breast Cancer 9 Romer et al, 2004, 2 Watkins et al, 2003, 3 Thayer et al, 2003, 4 Berman et al, 2003, Qualtrough et al 2004, 6
Slide 23: Abnormal Hedgehog Expression Supports Growth of Certain Cancers
Abnormal Hedgehog Expression Supports Growth of Certain Cancers Certain Cancers Hedgehog Protein Adjacent Stromal Cells Angiogenesis Factors Growth Factors VEGF, Ang-1, Ang-2 IGF-I,BDNF, NGF Certain Cancers Hedgehog Protein
Slide 24: Abnormal Hedgehog Expression Supports Growth of Certain Cancers
Abnormal Hedgehog Expression Supports Growth of Certain Cancers Certain Cancers Small Molecules Hedgehog Protein Antibodies Adjacent Stromal Cells Angiogenesis Factors Growth Factors VEGF, Ang-1, Ang-2 IGF-I,BDNF, NGF
Slide 25: Systemic Hh Antagonist - Update
Systemic Hh Antagonist - Update 1st Lead Clinical Drug Candidate Selected by Genentech IND filing for 1st Oncology indication anticipated 2H ’06 IND filing would result in a cash milestone payment to Curis Subsequent clinical development milestones would result in escalating cash payments to Curis
Slide 26: Partner-Program Status Update
Partner-Program Status Update Disco very Target Valid HTS Products Undisclosed Pathway Screens Med Preclinical IND Clinical Phases Chem Early Mid Late I II III Hh Oncology Hh Neurology Undisclosed Pathway Screens Hair Re-Growth Hh Agonist Screens BMP-7 BMP-7 Small Molecule Cardio Screens
Slide 27: Hedgehog Pathway is Activated in Response to Nerve Injury
Hedgehog Pathway is Activated in Response to Nerve Injury BLUE staining Relative Level of Hedgehog mRNA denotes presence of Hedgehog Day 0 Day 1 0 1 3 7 13 Time After Injury (days) Source: internal Curis research
Slide 28: Vehicle vs Hh Agonist Brain Slices
Vehicle Hh Agonist Photos of 5 brain slices (2mm)showing the effect of Hh agonist dosing 6 hrs post-MCAO. Slices are organized rostral (top) to caudal (bottom) through the forebrain of a vehicle and Hh agonist (3 mg/kg, iv) rat that were dosed 6 hrs post-MCAO onset. Slices were harvested 48 hrs post
Slide 29: Program Status Hh Agonist
Program Status Hh Agonist Lead Clinical Drug Candidate Selection 1H’07 (cash payment) IND filing approximately 12 months of lead selection (cash payment) Protein being evaluated for systemic cardiovascular validating proof of principle preclinical studies ongoing
Slide 30: Partner-Program Status Update
Partner-Program Status Update Disco very Target Valid HTS Products Undisclosed Pathway Screens Med Preclinical IND Clinical Phases Chem Early Mid Late I II III Hh Oncology Hh Neurology Undisclosed Pathway Screens Hair Re-Growth Hh Agonist Screens BMP-7 BMP-7 Small Molecule Cardio Screens
Slide 31: Hair Growth: R&D Agreement with P&G
Hair Growth R&D Agreement with P&G P&G receives a worldwide exclusive license to Curis’ Hedgehog agonist technology for dermatological indications Potential $100 million in cash payments, in addition to royalties and research support Curis will have the option to co-develop a product candidate from
Slide 32: Hedgehog Pathway Regulates Initiation of Hair Growth
Hedgehog Pathway Regulates Initiation of Hair Growth Hair Growth Model Day 4 Day 4 Stimulated Hair Follicles Source: internal Curis research Replicating Hair Follicle Cells Day 7 New Hair Shaft Growing
Slide 33: Small Molecule Hedgehog Agonist Promotes Hair Growth
Small Molecule Hedgehog Agonist Promotes Hair Growth Vehicle Treated Agonist Treated One dose, topical application, day 13 after treatment Source: internal Curis research
Slide 34: Program Status
Program Status 1st preclinical development objective reached; $1.0 M cash payment received 2nd preclinical development objective based upon lead candidate selection Expected Q1 2007; $1.8M cash payment IND filing anticipated within 12 months of lead selection IND would trigger cash milestone or Curi
Slide 35: Strong Intellectual Property Position
Strong Intellectual Property Position Hundreds of patents issued, allowed or pending in U.S. and abroad Compositions of matter covering signaling proteins, receptors, antibodies, small molecule agonists and antagonists, and others Fields of medical use including renal disorders, metabolic bone disea
Slide 36: Financial Data
Financial Data June 30, 2006 (amounts in 000’s except per share data) Cash, cash equivalents, investments $ 41,800 Accounts receivable $ Term debt $ 2,600 Shareholders’ equity $ 34,600 Basic shares outstanding 49,100 Fully diluted shares outstanding 61,600 YTD loss per share $ (0.16 )
Slide 37: Recent Pipeline Developments
Recent Pipeline Developments Hh Systemic Antagonist Genentech extended research funding to December 2006 Hh Systemic Small Molecule Agonist Wyeth extended research funding to February 2007 Hh Topical Small Molecule Agonist P&G hair growth collaboration signed September 2005 Achieved first preclinica
Slide 38: Recent Pipeline Developments
Recent Pipeline Developments Hh agonist for cardiovascular applications Data published supporting rationale of locally-delivered Hh agonist for use in treating heart attacks Continued efforts to find collaborator Discovery program developments Centocor relationship expanded Screening for BMP small m
Slide 39: Upcoming Objectives – Multi-Targeted Oncology Inhibitors
Upcoming Objectives – Multi-Targeted Oncology Inhibitors In Vivo efficacy in at least one multi-targeted inhibitor class of compounds; 2H 2006 Lead candidate selection; 1H 2007 IND application filing; 2H 2007
Slide 40: Upcoming Objectives - Hedgehog Programs
Upcoming Objectives - Hedgehog Programs Hh Systemic Antagonist IND filing for small molecule (Genentech) 2H 2006 Hh Systemic Small Molecule Agonist Lead candidate selection (Wyeth) Q1 2007 Dependent on adequate toxicity profile Hh Topical Small Molecule Agonist Lead candidate selection (P&G)1H 2007
Slide 41: Curis, Inc.
Curis, Inc. (NASDAQ: CRIS) Corporate Presentation September 12, 2006 Confidential September 12, 2006 41